Summary:
- This article discusses a patent dispute over Humira, the world's top-selling drug, which is used to treat autoimmune diseases like rheumatoid arthritis and Crohn's disease.
- The patent dispute is between the drug's manufacturer, AbbVie, and companies that want to make biosimilar versions of the drug, which are highly similar but not identical to the original.
- The article explains the complex legal and regulatory landscape around biologic drugs and the challenges of developing and approving biosimilar versions, which can improve access and lower costs for patients.